Trial Search Results

Dexamethasone Therapy in VLBW Infants at Risk of CLD

Infants who are on breathing support are often treated with steroids (dexamethasone); however, the best timing of therapy is not known. This trial looked at the benefits and hazards of starting dexamethasone therapy at two weeks of age and four weeks of age in premature infants.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

NICHD Neonatal Research Network

Collaborator: National Center for Research Resources (NCRR)

Stanford Investigator(s):


  • Drug: Dexamethasone Early
  • Drug: Dexamethasone Late


Phase 3


Inclusion criteria:

   - 501 to 1500 grams

   - 13 to 15 days old

   - Respiratory-index score of greater than or equal to 2.4 that had been increasing or
   minimally decreasing during the previous 48 hours or a score of greater than or equal
   to 4.0 even if there had been improvement during the preceding 48 hours

Exclusion criteria:

   - Received glucocorticoid treatment after birth

   - Had evidence or suspicious signs of sepsis as judged by the treating physician

   - Major congenital anomaly of the cardiovascular, pulmonary, or central nervous system

Ages Eligible for Study

13 Days - 15 Days

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting